An observational study in Deficiency, Vitamin C, Chronic Disease and Acute Disease, sponsored by Pascoe Pharmazeutische Praeparate GmbH. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Pascoe Pharmazeutische Praeparate GmbH · Observational
The goal of this observational study is to learn more about the disease and the symptoms where the product will use and in which patient groups. Further on, it is interesting to know clinical pictures, the symptoms improve. Patients with acute or chronical disease with vitamin c deficiency could be involved.
The main questions it aims to answer are:
The aim of this long-term observational study is to document the use of Vitamin C Injektopas® 7.5g in patients with vitamin C deficiency. The deficiency condition can be diagnosed either by laboratory diagnosis or clinically, i.e. symptomatically on the basis of general vitamin C deficiency symptoms (e.g. weakness, fatigue, susceptibility to infections and psychological complaints such as depressive moods) through to more specific deficiency symptoms, which are primarily related to impaired collagen formation and therefore primarily affect connective tissue, blood vessels, cartilage and bones. These include, above all, haemorrhages in the skin, inflamed and bleeding gums - through to tooth loss, joint effusions, pain in the joints, bones and muscles as well as poorly healing wounds, etc.
The survey should be used to assess the disease underlying the vitamin C deficiency (the so-called underlying disease), the reduction in the symptoms of the disease under therapy and also the tolerability. Both acute and chronic underlying diseases should be taken into account.
In addition to the symptom enquiry, the global assessment of the efficacy and tolerability of therapy with Vitamin C Injektopas® 7.5g is evaluated.
Patients with a vitamin C deficiency due to acute or chronic underlying diseases
Exclusion Criteria:
Patients with vitamin C deficiency due to a acute underlying disease treated with Vitamin-C injektopas® 7.5 g
Patients with vitamin C deficiency due to a chronic underlying disease treated with Vitamin-C injektopas® 7.5 g
change in general and disease-specific symptoms
The main aim was to measure the success of the treatment with Vitamin C-Injektopas® 7,5g by the documentation of the change in general and disease-specific symptoms. The symptoms are measured by a score: 0 = not present, 1 = slightly, 2 = moderate and 3 = strong The change of the symptoms is measured in change groups: * number of patients with improved symptoms * number of patients with unchanged symptoms * number of patients with worsened symptoms
Time frame: therapy duration, an expected average of 3 weeks (for acute diseases) or 12 weeks (for chronic diseases)
Global assessment of efficacy of treatment with Vitamin C-Injektopas® 7,5g
Global assessment of efficacy is measured by a score: * Very good efficacy (complete regression of symptoms) * Good efficacy (symptoms was much improved) * Moderate efficacy (symptoms was slightly improved) * No efficacy (symptoms remained unchanged) * No efficacy (symptoms worsened)
Time frame: therapy duration, an expected average of 3 weeks (for acute diseases) or 12 weeks (for chronic diseases)
Dosage scheme
Number of infusions during the observational time
Time frame: Number of infusions through study completion, up to appr. 12 weeks
Global Assessment of Tolerability
Global Assessment of Tolerability of the treatment with Vitamin C-Injektopas® 7,5g Global assessment of tolerability is measured by a score: * Very good tolerability (no side effects) * Poor tolerability (side effects occurred)
Time frame: on last visit, an expected average of 3 weeks (for acute diseases) or 12 weeks (for chronic diseases)
Quality of life in chronic disease (Numeric Scale)
Quality of life in chronic disease, Numeric Scale (NRS) from 0 - 10
Time frame: therapy duration, an expected average of 12 weeks (for chronic diseases)
Plan to share: No — All data are anonymous. Patient data list only will be sent to regulatory authorities.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ascorbic Acid Deficiency
Pascoe Pharmazeutische Praeparate GmbH